Cell Source, Inc. (CLCS)
Cell Source, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.82, up 0.00% on the session, giving a market capitalisation of $55.9M. On trailing twelve-month figures it carries a trailing P/E of -8.23, a net margin of 0.0%. Its beta of -157.98 implies it has historically moved less than the broad market.
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Cell Source, Inc. is most often compared with the following Healthcare names: